Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.48 |
| ▸ | FLT1 | P17948 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | PRKACA | P17612 | 2/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.34 |
| ▸ | GSK3A | P49840 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | PRKX | P51817 | 1/20 | 0.34 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.34 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181413 | 0.84 | QPCT (0.33) | KDR | |
| SCHEMBL4173263 | 0.82 | KDR (0.40) | KDRFLT1 | |
| SCHEMBL4180846 | 0.74 | TUBB4A (0.43) | KDRDYRK1ACLK4 | |
| SCHEMBL4174196 | 0.73 | KDM4E (0.37) | KDRCLK4 | |
| SCHEMBL4178551 | 0.73 | KDR (0.36) | KDRFLT1FLT4 | |
| SCHEMBL4181723 | 0.73 | CYP1A2 (0.42) | KDRMAPK1DYRK1ACLK4 | |
| SCHEMBL4170614 | 0.72 | KDR (0.43) | KDRMAPK1CLK4 | |
| SCHEMBL4174883 | 0.72 | KDR (0.69) | KDRFLT1JAK3IRAK4 | |
| SCHEMBL4178025 | 0.71 | TUBB4A (0.38) | KDRGSK3BRPS6KB1AURKA | |
| SCHEMBL4173085 | 0.71 | KDR (0.50) | KDRFLT1CDK2CDC7CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | KDR 3284/4885FLT1 3408/4885CDK2 53/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | KDR 3284/4885FLT1 3408/4885CDK2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.